Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010053023> ?p ?o ?g. }
- W3010053023 endingPage "718" @default.
- W3010053023 startingPage "718" @default.
- W3010053023 abstract "Importance It is uncertain whether and when angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin II receptor blocker (ARB) treatment should be discontinued in individuals with low estimated glomerular filtration rate (eGFR). Objective To investigate the association of ACE-I or ARB therapy discontinuation after eGFR decreases to below 30 mL/min/1.73 m2with the risk of mortality, major adverse cardiovascular events (MACE), and end-stage kidney disease (ESKD). Design, Setting, and Participants This retrospective, propensity score–matched cohort study included 3909 patients from an integrated health care system that served rural areas of central and northeastern Pennsylvania. Patients who initiated ACE-I or ARB therapy from January 1, 2004, to December 31, 2018, and had an eGFR decrease to below 30 mL/min/1.73 m2during therapy were enrolled, with follow-up until January 25, 2019. Exposures Individuals were classified based on whether they discontinued ACE-I or ARB therapy within 6 months after an eGFR decrease to below 30 mL/min/1.73 m2. Main Outcomes and Measures The association between ACE-I or ARB therapy discontinuation and mortality during the subsequent 5 years was assessed using multivariable Cox proportional hazards regression models, adjusting for patient characteristics at the time of the eGFR decrease in a propensity score–matched sample. Secondary outcomes included MACE and ESKD. Results Of the 3909 individuals receiving ACE-I or ARB treatment who experienced an eGFR decrease to below 30 mL/min/1.73 m2(2406 [61.6%] female; mean [SD] age, 73.7 [12.6] years), 1235 discontinued ACE-I or ARB therapy within 6 months after the eGFR decrease and 2674 did not discontinue therapy. A total of 434 patients (35.1%) who discontinued ACE-I or ARB therapy and 786 (29.4%) who did not discontinue therapy died during a median follow-up of 2.9 years (interquartile range, 1.3-5.0 years). In the propensity score–matched sample of 2410 individuals, ACE-I or ARB therapy discontinuation was associated with a higher risk of mortality (hazard ratio [HR], 1.39; 95% CI, 1.20-1.60]) and MACE (HR, 1.37; 95% CI, 1.20-1.56), but no statistically significant difference in the risk of ESKD was found (HR, 1.19; 95% CI, 0.86-1.65). Conclusions and Relevance The findings suggest that continuing ACE-I or ARB therapy in patients with declining kidney function may be associated with cardiovascular benefit without excessive harm of ESKD." @default.
- W3010053023 created "2020-03-13" @default.
- W3010053023 creator A5010621055 @default.
- W3010053023 creator A5027932235 @default.
- W3010053023 creator A5036099699 @default.
- W3010053023 creator A5047227825 @default.
- W3010053023 creator A5047540616 @default.
- W3010053023 creator A5054296834 @default.
- W3010053023 creator A5073143396 @default.
- W3010053023 creator A5073587735 @default.
- W3010053023 date "2020-05-01" @default.
- W3010053023 modified "2023-10-12" @default.
- W3010053023 title "Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate" @default.
- W3010053023 cites W1966220462 @default.
- W3010053023 cites W1991106789 @default.
- W3010053023 cites W1995987873 @default.
- W3010053023 cites W1996351770 @default.
- W3010053023 cites W2038981426 @default.
- W3010053023 cites W2041725636 @default.
- W3010053023 cites W2044545030 @default.
- W3010053023 cites W2044773944 @default.
- W3010053023 cites W2046404715 @default.
- W3010053023 cites W2063210769 @default.
- W3010053023 cites W2077126024 @default.
- W3010053023 cites W2099433404 @default.
- W3010053023 cites W2100124500 @default.
- W3010053023 cites W2104266516 @default.
- W3010053023 cites W2126049444 @default.
- W3010053023 cites W2136133622 @default.
- W3010053023 cites W2147804563 @default.
- W3010053023 cites W2155965977 @default.
- W3010053023 cites W2207247573 @default.
- W3010053023 cites W2284501626 @default.
- W3010053023 cites W2557827104 @default.
- W3010053023 cites W2749616207 @default.
- W3010053023 cites W2768267412 @default.
- W3010053023 cites W2820917509 @default.
- W3010053023 cites W2954688640 @default.
- W3010053023 cites W2970412630 @default.
- W3010053023 cites W2980164571 @default.
- W3010053023 cites W4247391753 @default.
- W3010053023 doi "https://doi.org/10.1001/jamainternmed.2020.0193" @default.
- W3010053023 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7063544" @default.
- W3010053023 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32150237" @default.
- W3010053023 hasPublicationYear "2020" @default.
- W3010053023 type Work @default.
- W3010053023 sameAs 3010053023 @default.
- W3010053023 citedByCount "90" @default.
- W3010053023 countsByYear W30100530232020 @default.
- W3010053023 countsByYear W30100530232021 @default.
- W3010053023 countsByYear W30100530232022 @default.
- W3010053023 countsByYear W30100530232023 @default.
- W3010053023 crossrefType "journal-article" @default.
- W3010053023 hasAuthorship W3010053023A5010621055 @default.
- W3010053023 hasAuthorship W3010053023A5027932235 @default.
- W3010053023 hasAuthorship W3010053023A5036099699 @default.
- W3010053023 hasAuthorship W3010053023A5047227825 @default.
- W3010053023 hasAuthorship W3010053023A5047540616 @default.
- W3010053023 hasAuthorship W3010053023A5054296834 @default.
- W3010053023 hasAuthorship W3010053023A5073143396 @default.
- W3010053023 hasAuthorship W3010053023A5073587735 @default.
- W3010053023 hasBestOaLocation W30100530231 @default.
- W3010053023 hasConcept C126322002 @default.
- W3010053023 hasConcept C126894567 @default.
- W3010053023 hasConcept C134018914 @default.
- W3010053023 hasConcept C159641895 @default.
- W3010053023 hasConcept C170493617 @default.
- W3010053023 hasConcept C198710026 @default.
- W3010053023 hasConcept C2778468042 @default.
- W3010053023 hasConcept C2778715236 @default.
- W3010053023 hasConcept C71924100 @default.
- W3010053023 hasConcept C84393581 @default.
- W3010053023 hasConceptScore W3010053023C126322002 @default.
- W3010053023 hasConceptScore W3010053023C126894567 @default.
- W3010053023 hasConceptScore W3010053023C134018914 @default.
- W3010053023 hasConceptScore W3010053023C159641895 @default.
- W3010053023 hasConceptScore W3010053023C170493617 @default.
- W3010053023 hasConceptScore W3010053023C198710026 @default.
- W3010053023 hasConceptScore W3010053023C2778468042 @default.
- W3010053023 hasConceptScore W3010053023C2778715236 @default.
- W3010053023 hasConceptScore W3010053023C71924100 @default.
- W3010053023 hasConceptScore W3010053023C84393581 @default.
- W3010053023 hasIssue "5" @default.
- W3010053023 hasLocation W30100530231 @default.
- W3010053023 hasLocation W30100530232 @default.
- W3010053023 hasOpenAccess W3010053023 @default.
- W3010053023 hasPrimaryLocation W30100530231 @default.
- W3010053023 hasRelatedWork W1977123261 @default.
- W3010053023 hasRelatedWork W2044747643 @default.
- W3010053023 hasRelatedWork W2047608102 @default.
- W3010053023 hasRelatedWork W2068374317 @default.
- W3010053023 hasRelatedWork W2077998387 @default.
- W3010053023 hasRelatedWork W2078291669 @default.
- W3010053023 hasRelatedWork W2117060894 @default.
- W3010053023 hasRelatedWork W2126797993 @default.
- W3010053023 hasRelatedWork W2149410839 @default.
- W3010053023 hasRelatedWork W2418574610 @default.
- W3010053023 hasVolume "180" @default.